Sugi Predict

Sugi Predict / Compounds / SCHEMBL35539

SCHEMBL35539

SCHEMBL35539

CNS(=O)(=O)c1cccc(C(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.66
▸ CA2 P00918 1/20 0.66
▸ CYP2C19 P33261 1/20 0.62
▸ F2 P00734 3/20 0.60
▸ PRSS1 P07477 3/20 0.60
▸ PRSS2 P07478 3/20 0.60
▸ PRSS3 P35030 3/20 0.60
▸ MEP1B Q16820 2/20 0.59
▸ AKR1C3 P42330 4/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ PTK2B Q14289 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ PTBP1 P26599 1/20 0.57
▸ KMT2A Q03164 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ MAPT P10636 1/20 0.55
▸ PFKFB3 Q16875 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147625 1.00 CA1 (0.66) CA1CA2CYP2C19F2PRSS1
SCHEMBL4057326 0.86 ALDH1A1 (0.65) LMNAPTBP1KMT2ATDP1MAPT
SCHEMBL2854385 0.84 LMNA (0.56) CA1CA2F2PRSS1PRSS2
SCHEMBL12060827 0.84 LMNA (0.63) AKR1C3LMNAPTBP1KMT2ATDP1
SCHEMBL3245644 0.84 CA1 (0.68) CA1CA2CYP2C19F2PRSS1
SCHEMBL22916896 0.84 CA1 (0.68) CA1CA2CYP2C19F2PRSS1
SCHEMBL3476507 0.83 TDP1 (0.60) CA1CA2KDM4ETSHRLMNA
SCHEMBL15625455 0.83 CA1 (0.62) CA1CA2CYP2C19F2PRSS1
SCHEMBL13543487 0.83 CA1 (0.62) CA1CA2CYP2C19F2PRSS1
SCHEMBL4140365 0.82 PFKFB3 (0.58) CA1CA2PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 — — CN claimed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
WO-2025099307-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2025-05-15 — — WO disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 — — US disclosed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 — — WO disclosed
EP-1322611-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-07-02 — — EP disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 — — US disclosed
EP-1274701-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-01-15 — — EP disclosed
US-20020077337-A1 Chemical compounds ASTRAZENECA AB (SE) 2002-06-20 — — US disclosed
WO-2002020484-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-03-14 — — WO disclosed
WO-2001077101-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed
EP-0159291-A1 Ink composition for the ink-jet printing process CIBA-GEIGY AG (CH) 1985-10-23 — — EP disclosed
EP-0068700-A1 Azobicycloalkylbenzamides, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-01-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077337-A1 Chemical compounds CCR3, CCR1, CCR4 CA1 495/4885CA2 1477/4885CYP2C19 1230/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS CA1 3083/4885CA2 1016/4885CYP2C19 1866/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB CA1 4780/4885CA2 4715/4885CYP2C19 3974/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 CA1 966/4885CA2 2006/4885CYP2C19 439/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS CA1 3083/4885CA2 1016/4885CYP2C19 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.